SLS - SELLAS Life Sciences Group, Inc.
Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher on Wednesday as traders react to the company's latest update on its acute myeloid leukemia pipeline and the timeline for a pivotal Phase 3 readout. Here's what investors need to know.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum Format: Corporate Presentation and Fireside Chat Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET Location: New York, NY Webcast Link: Click here A.G.P.
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline.
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) shares gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $5.20, but opened at $5.60. SELLAS Life Sciences Group shares last traded at $5.4990, with a volume of 2,307,376 shares traded. The company
A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ( NASDAQ:SLS ) is at a genuinely unusual inflection point.
SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Profitability This table compares SELLAS Life
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - - Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 –
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) has surged over 200% over the last six months, with a year-to-date stock jump of around 45%.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw some unusual options trading activity on Monday. Investors purchased 42,324 call options on the stock. This is an increase of approximately 54% compared to the average volume of 27,474 call options. Institutional Investors Weigh In On SELLAS Life Sciences Group Several hedge funds have
Solaris Resources Inc. (TSE: SLS - Get Free Report)'s share price reached a new 52-week high during trading on Friday. The stock traded as high as C$13.12 and last traded at C$12.97, with a volume of 146895 shares changing hands. The stock had previously closed at C$12.68. Wall Street Analysts Forecast Growth A number of